Clinical trials: Incurable Disease
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma
RATIONALE: AT7519M may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT7519M in treating patients with advanced…
- Trial name
- NCT00390117
- Testing
- CDKI AT7519, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Melanoma
Phase I trial to study the effectiveness of vaccine therapy in treating patients with melanoma that cannot be treated with surgery. Vaccines may make the body build an immune response that may kill tumor cells.
- Trial name
- NCT00003556
- Testing
- ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in patients who have relapsed or refractory…
- Trial name
- NCT00036946
- Testing
- ziv-aflibercept
- Where
- United States
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumor, Unspecified, Adult, Haematological Malignancy
Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
Proseq Cancer is a precision medicine program based on in-house whole exome sequencing (WES) and RNA sequencing. The approved protocol allows for biobanking, registration of clinical and laboratory data, and sharing of genomic…
- Trial name
- NCT05695638
- Where
- Denmark
- Volunteers
- 3,000 people
- Sponsor
- Morten Ladekarl
Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system.
- Trial name
- NCT02655822
- Testing
- Ciforadenant, Ciforadenant + atezolizumab
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 502 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
This phase II trial studies how well targeted therapy works in treating patients with incurable non-small cell lung cancer with a genetic mutation.
- Conditions
- EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT02949843
- Testing
- Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Trial name
- NCT05904080
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 92 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Title XELOX FOR SALIVARY GLAND CANCERS
The goal of this clinical research study is to find out how effective oxaliplatin and capecitabine are against advanced cancer of the salivary gland.
- Trial name
- NCT00101075
- Testing
- Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or…
- Trial name
- NCT00045266
- Testing
- ziv-aflibercept
- Where
- United States
- Sponsor
- Regeneron Pharmaceuticals
Head and Neck Cancer
Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be an effective palliative treatment for head and neck cancer.
- Trial name
- NCT00003856
- Testing
- temoporfin
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Quintiles, Inc.
Hepatocellular Carcinoma
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
- Trial name
- NCT07691762
- Testing
- SHR-8068 + Adebrelimab + Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 690 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer
8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer
An open randomized phase III study to compare 8 continuous cycles of chemotherapy with 8 cycles of intermittent (2 times 4 cycles) chemotherapy in first line treatment, in combination with bevacizumab, and second line treatment…
- Trial name
- Stop&Go (NCT01935492)
- Testing
- Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
- Where
- Netherlands
- Volunteers
- 420 people
- Sponsor
- Borstkanker Onderzoek Groep
Metastatic Colorectal Cancers, Metastatic Gastric Cancers
Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
Prospective non randomized, non-comparative, dose escalation, two arms open phase I trial to assess the safety and tolerability of capecitabine given in combination with aflibercept in patients with measurable or evaluable…
- Conditions
- Metastatic Colorectal Cancers, Metastatic Gastric Cancers, Metastatic Oesophageal Cancers, Metastatic Pancreatic Cancers
- Trial name
- MOMENTUM1 (NCT01843725)
- Testing
- capecitabine, aflibercept
- Where
- Belgium
- Volunteers
- 37 people
- Sponsor
- Jules Bordet Institute
Cancer Disease, Palliative Therapy
Assessment of Disease Burden and Palliative Care Needs of Patients During the Course of Incurable Cancer Disease
The aim of this non-investigational study is to determine the symptoms and disease burden at the time point of diagnosis and in the further course of an incurable cancer disease.
- Trial name
- APM-Project (NCT02751723)
- Testing
- validated questionnaires
- Where
- 21 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Florian Lordick, MD
Melanoma
A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma
This will show if CP-675,206 can be administered safely as an intravenous infusion lasting one hour. CP 675,206 already has been administered to 835 subjects over 1.0 - 7.5 hours.
- Trial name
- NCT00585000
- Testing
- CP-675,206
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Metastatic Solid Tumor, Lymphoma
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies
NOTE: This study is now recruiting only patients with Myeloproliferative Neoplasms (MPN). Dose escalation has been completed. The purpose of this study is to test a new drug, called PU-H71 for the first time in humans, to find…
- Conditions
- Metastatic Solid Tumor, Lymphoma, Myeloproliferative Neoplasms (MPN)
- Trial name
- NCT01393509
- Testing
- PU-H71
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
AZD2281 and Irinotecan in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: AZD2281 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00535353
- Testing
- irinotecan hydrochloride, olaparib
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- NCIC Clinical Trials Group
Cancer of Head and Neck, Cancer of Cervix
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer
This research study is studying a therapeutic vaccine, named DPX-E7, as a possible treatment for Human Papilloma Virus or HPV related head and neck, cervical or anal cancer (positive for HLA-A*02).
- Conditions
- Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus
- Trial name
- NCT02865135
- Testing
- DPX-E7 vaccine, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
HCC - Hepatocellular Carcinoma
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
This is a single-arm, open-label Phase IIa study designed to evaluate the efficacy, safety, and PK of CVM-1118 in combination with Sintilimab (Tyvyt ®) and TACE in participants with incurable/non-metastatic HCC.
- Trial name
- NCT07521852
- Testing
- CVM-1118 + Sintilimab + TACE
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- TaiRx, Inc.
Hepatocellular Carcinoma
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
- Trial name
- NCT06371157
- Testing
- AK104, Lenvatinib, TACE
- Where
- 4 sites in China
- Volunteers
- 469 people
- Sponsor
- Akeso